Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity

2008/12/17 by Balasubramanyam Karanam, Ratish Gambhira, Shiwen Peng +8 · 23 citations
Medicine · Immunology and Microbiology · #Cervical Cancer and HPV Research #Immunotherapy and Immune Responses #Poxvirus research and outbreaks

paper · doi:10.1016/j.vaccine.2008.11.099

Cited by

• Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
• Development of HPV nanovaccine candidate based on IL-15-E7 fusion protein encapsulated in silk-fibroin nanoparticles
• Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. [europepmc]
• Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. [europepmc]
• A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. [europepmc]
• A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. [europepmc]
• Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. [europepmc]
• Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis. [europepmc]
• Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania. [europepmc]
• Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. [europepmc]
• Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. [europepmc]
• Progress and prospects for L2-based human papillomavirus vaccines. [europepmc]
• Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. [europepmc]
• Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer. [europepmc]
• Saponins from Quillaja saponaria and Quillaja brasiliensis : Particular Chemical Characteristics and Biological Activities. [europepmc]
• A batch-effect adjusted Simon's two-stage design for cancer vaccine clinical studies. [europepmc]
• Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases. [europepmc]
• RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. [europepmc]
• Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. [europepmc]
• New Perspectives in Therapeutic Vaccines for HPV: A Critical Review. [europepmc]
• The Interaction of Human Papillomavirus Infection and Prostaglandin E 2 Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics. [europepmc]
• Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice. [europepmc]
• A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer. [europepmc]